Developing new therapies for eye diseases using advanced drug delivery systems
Ophthalmic Therapeutics Engineering Core
['FUNDING_P30'] · UNIVERSITY OF SOUTHERN CALIFORNIA · NIH-10930031
This study is working on new ways to deliver medicine directly to the eye to help improve treatments for eye diseases, so patients can have more effective options for their conditions.
Quick facts
| Phase | ['FUNDING_P30'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTHERN CALIFORNIA (nih funded) |
| Locations | 1 site (Los Angeles, UNITED STATES) |
| Trial ID | NIH-10930031 on ClinicalTrials.gov |
What this research studies
The Ophthalmic Therapeutics Engineering Core focuses on creating innovative therapies for ocular diseases by utilizing advanced drug delivery systems. This research provides essential resources and technical expertise to develop and optimize molecular nano-assemblies that can carry drugs directly to targeted areas in the eye. By bridging basic science and engineering, the Core aims to enhance the effectiveness of therapeutic applications through improved instrumentation and device engineering. Patients may benefit from new treatment options that are more precise and effective in addressing their eye conditions.
Who could benefit from this research
Good fit: Ideal candidates include individuals suffering from ocular diseases who may benefit from advanced drug delivery therapies.
Not a fit: Patients with non-ocular conditions or those who do not require advanced drug delivery systems may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for various ocular diseases.
How similar studies have performed: Other research has shown success in developing targeted drug delivery systems for ocular therapies, indicating a promising approach.
Where this research is happening
Los Angeles, UNITED STATES
- UNIVERSITY OF SOUTHERN CALIFORNIA — Los Angeles, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHOU, QIFA — UNIVERSITY OF SOUTHERN CALIFORNIA
- Study coordinator: ZHOU, QIFA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.